These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36959766)

  • 1. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
    Caputo SA; Hawkins M; Jaeger EB; Fleming W; Casado C; Manogue C; Huang M; Lieberman A; Light M; Sussman IP; Miller P; Barata PC; Lewis BE; Layton JL; Ledet EM; Antonarakis ES; Sartor O
    Prostate; 2023 Jun; 83(9):879-885. PubMed ID: 36959766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
    J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
    Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
    Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
    Markowski MC; Kachhap S; De Marzo AM; Sena LA; Luo J; Denmeade SR; Antonarakis ES
    Clin Genitourin Cancer; 2022 Apr; 20(2):97-101. PubMed ID: 34538582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
    Alumkal JJ; Sun D; Lu E; Beer TM; Thomas GV; Latour E; Aggarwal R; Cetnar J; Ryan CJ; Tabatabaei S; Bailey S; Turina CB; Quigley DA; Guan X; Foye A; Youngren JF; Urrutia J; Huang J; Weinstein AS; Friedl V; Rettig M; Reiter RE; Spratt DE; Gleave M; Evans CP; Stuart JM; Chen Y; Feng FY; Small EJ; Witte ON; Xia Z
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12315-12323. PubMed ID: 32424106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
    Schweizer MT; Gulati R; Yezefski T; Cheng HH; Mostaghel E; Haffner MC; Patel RA; De Sarkar N; Ha G; Dumpit R; Woo B; Lin A; Panlasigui P; McDonald N; Lai M; Nega K; Hammond J; Grivas P; Hsieh A; Montgomery B; Nelson PS; Yu EY
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):194-200. PubMed ID: 36564459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
    Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
    Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
    Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Denmeade S; Lim SJ; Isaaccson Velho P; Wang H
    Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
    Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V
    Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
    Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
    Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.